Research Nester has released a report titled “CDK 4/6 Inhibitor Drugs Market: Global Demand Analysis & Opportunity Outlook 2030” which also includes some of the prominent market analyzing parameters such as industry growth drivers, restraints, supply and demand risk, along with the impact of COVID-19 and a detailed discussion on the latest trends and future opportunities that are associated with the growth of the market.
2.3 Million women were diagnosed with breast cancer around the globe in the year 2020, according to the statistics by the World Bank. Additionally, the statistics also stated that in the same year, 685000 deaths were registered due to the disease.
The statistics portray the growing prevalence of breast cancer worldwide and the increasing number of deaths caused due to the disease, which is driving the need for early detection and treatment of the disease amongst these patients. The CDK 4/6 inhibitor drugs are one of the most widely preferred drugs for the treatment of breast cancer, backed by its high efficiency as compared to other drugs available. As a result, there is a growing demand for these drugs, which is one of the major factors anticipated to drive the growth of the global CDK 4/6 inhibitor drugs market in the coming years.
The global CDK 4/6 inhibitor drugs market is anticipated to grow with a CAGR of 13.2% over the forecast period, i.e., 2021 – 2030. The market is estimated to garner a revenue of USD 42511.38 Million by the end of 2030, up from a revenue of USD 6991.70 Million in the year 2020. The market is segmented by drug type into palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). By the end of 2030, out of all the other segments, the palbociclib (Ibrance) segment is expected to generate the largest revenue of USD 37659.17 Million, and further grow with the highest CAGR of 13.4% during the forecast period. Additionally, in the year 2020, the segment generated a revenue of USD 5391.08 Million.
Access our detailed report at:
https://www.researchnester.com/reports/cdk-46-inhibitor-drugs-market/2533
Geographically, the global CDK 4/6 inhibitor drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. By the end of 2030, out of the market in all these regions, the market in North America region is anticipated to garner the largest revenue of USD 30204.34 Million, up from a revenue of USD 4992.07 Million in the year 2020.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
However, the high cost of the drug, and the concern for the side effects associated with the drug are predicted to hinder the market growth.
This report also provides the existing competitive scenario of some of the key players of the global CDK 4/6 inhibitor drugs market, which includes company profiling of Pfizer Inc., Novartis AG, Eli Lilly and Company, and others.
The profiling enfolds key information of the companies which comprises of business overview, products and services, key financials and recent news and developments. Conclusively, the report titled “CDK 4/6 Inhibitor Drugs Market: Global Demand Analysis & Opportunity Outlook 2030”, analyses the overall global CDK 4/6 inhibitor drugs industry to help new entrants to understand the details of the market. In addition to that, this report also guides existing players looking for expansion and major investors looking for investment in the global CDK 4/6 inhibitor drugs market in the near future.
Request Report Sample@
https://www.researchnester.com/sample-request-2533
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
Contact Us:
AJ Daniel
Email: [email protected]
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919